Vir Biotechnology (VIR) Operating Leases (2020 - 2026)

Vir Biotechnology has reported Operating Leases for 7 years, with the latest figure at $86.6 million in Q1 2026.

• Quarterly Operating Leases fell 1.74% year-over-year to $86.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $86.6 million (down 1.74% YoY) and the FY2025 annual result came in at $89.1 million, down 9.03% from the prior year.
• Operating Leases retreated to $86.6 million in Q1 2026 per VIR's latest filing, from $89.1 million in the prior quarter.
• Over five years, Operating Leases peaked at $132.8 million in Q1 2022 and troughed at $86.6 million in Q1 2026.
• A 5-year average of $107.2 million and a median of $109.2 million in 2024 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2022 and 2024: Operating Leases jumped 99.37% in 2022, then dropped 19.35% in 2024.
• Over 5 years, Operating Leases stood at $123.8 million in 2022, then fell by 9.82% to $111.7 million in 2023, then fell by 12.34% to $97.9 million in 2024, then fell by 9.03% to $89.1 million in 2025, then dropped by 2.72% to $86.6 million in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $86.6 million, $89.1 million, and $91.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.